WO2002047672A3 - Treatment of cystic fibrosis with alkalinizing agents - Google Patents
Treatment of cystic fibrosis with alkalinizing agents Download PDFInfo
- Publication number
- WO2002047672A3 WO2002047672A3 PCT/US2001/047764 US0147764W WO0247672A3 WO 2002047672 A3 WO2002047672 A3 WO 2002047672A3 US 0147764 W US0147764 W US 0147764W WO 0247672 A3 WO0247672 A3 WO 0247672A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cystic fibrosis
- treatment
- alkalinizing agents
- alkalinizing
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002228970A AU2002228970A1 (en) | 2000-12-11 | 2001-12-07 | Treatment of cystic fibrosis with alkalinizing agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25471200P | 2000-12-11 | 2000-12-11 | |
US60/254,712 | 2000-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002047672A2 WO2002047672A2 (en) | 2002-06-20 |
WO2002047672A3 true WO2002047672A3 (en) | 2003-05-15 |
Family
ID=22965287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/047764 WO2002047672A2 (en) | 2000-12-11 | 2001-12-07 | Treatment of cystic fibrosis with alkalinizing agents |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002228970A1 (en) |
WO (1) | WO2002047672A2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012470A1 (en) * | 1994-10-20 | 1996-05-02 | Alphagene, Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
WO1996034604A1 (en) * | 1995-05-05 | 1996-11-07 | Novartis Ag | Inhibition of intracellular acidification |
US5723496A (en) * | 1991-03-05 | 1998-03-03 | The Regents Of University Of California | Method for prevention and treatment of harmful effects of intracellular acidosis |
US5908611A (en) * | 1995-05-05 | 1999-06-01 | The Scripps Research Institute | Treatment of viscous mucous-associated diseases |
-
2001
- 2001-12-07 AU AU2002228970A patent/AU2002228970A1/en not_active Abandoned
- 2001-12-07 WO PCT/US2001/047764 patent/WO2002047672A2/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723496A (en) * | 1991-03-05 | 1998-03-03 | The Regents Of University Of California | Method for prevention and treatment of harmful effects of intracellular acidosis |
WO1996012470A1 (en) * | 1994-10-20 | 1996-05-02 | Alphagene, Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
WO1996034604A1 (en) * | 1995-05-05 | 1996-11-07 | Novartis Ag | Inhibition of intracellular acidification |
US5908611A (en) * | 1995-05-05 | 1999-06-01 | The Scripps Research Institute | Treatment of viscous mucous-associated diseases |
Non-Patent Citations (4)
Title |
---|
AXELSSON M A B ET AL: "Neutralization of pH in the Golgi apparatus causes redistribution of glycosyltransferases and changes in the O-glycosylation of mucins", GLYCOBIOLOGY, (AUG 2001) VOL. 11, NO. 8, PP. 633-644. PUBLISHER: OXFORD UNIV PRESS INC, JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA. ISSN: 0959-6658., Univ Gothenburg, Dept Biochem Med, POB 440, S-40530 Gothenburg, Sweden (Reprint);Univ Gothenburg, Dept Biochem Med, S-40530 Gothenburg, Sweden; EMBL, Cell Biol & Biophys Programme, D-69017 Heidelberg,, XP008005946 * |
POSCHET J F ET AL: "Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 24, 20 November 2001 (2001-11-20), November 20, 2001, pages 13972 - 13977, XP001089858, ISSN: 0027-8424 * |
POSCHET JENS F ET AL: "Hyperacidification of cellubrevin endocytic compartments and defective endosomal recycling in cystic fibrosis respiratory epithelial cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 16, 19 April 2002 (2002-04-19), April 19, 2002, pages 13959 - 13965, XP001089863, ISSN: 0021-9258 * |
POSCHET JENS F ET AL: "Trans-Golgi network and cellubrevin endosomal compartments are hyperacidified in cystic fibrosis lung epithelial cells.", MOLECULAR BIOLOGY OF THE CELL, vol. 11, no. Supplement, December 2000 (2000-12-01), 40th American Society for Cell Biology Annual Meeting;San Francisco, CA, USA; December 09-13, 2000, pages 134a, XP008005913, ISSN: 1059-1524 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002228970A1 (en) | 2002-06-24 |
WO2002047672A2 (en) | 2002-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20013554L (en) | Anticonvulsant derivatives that can be used in the treatment of cluster headaches | |
MXPA03005893A (en) | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs. | |
ID28981A (en) | HEKSANA 3-AZABISIKLO (3.1.0) USES IN THERAPY | |
TR200002773T2 (en) | Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's. | |
AU2001237996A1 (en) | Thermally and chemically treating cells | |
AU2002211379A1 (en) | Compositions and methods for treatment of cystic fibrosis | |
IS5504A (en) | Composition active in the treatment of impotence | |
HK1045302A1 (en) | Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders. | |
NO20013493L (en) | Use of neurotrophin and its analogues in the treatment of gastrointestinal hypomotility disorders | |
IL161667A0 (en) | Method and composition to treat cystic fibrosis | |
AU3262797A (en) | Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv | |
WO2003039453A3 (en) | Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use | |
NO20033434D0 (en) | 3,7-diazabicyclo (3.3.0) octanes and their use in the treatment of cardiac arrhythmias | |
AU2002227247A1 (en) | Biofilm therapy process and elements | |
WO2002047672A3 (en) | Treatment of cystic fibrosis with alkalinizing agents | |
AU2001296173A1 (en) | 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias | |
WO2003032899A3 (en) | Methods and materials for targeting and affecting selected cells | |
AU9352401A (en) | Production process and composition of an enzymatic preparation, and its use for the treatment of domestic and industrial effluents of high fat, protein and/or carbohydrate content | |
AU2001275959A1 (en) | Method of treating the syndrome of type 2 diabetes in humans | |
AU2001261360A1 (en) | R-eliprodil for treating glaucoma | |
HU9903098D0 (en) | Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv | |
ZA991319B (en) | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia. | |
HK1056828A1 (en) | Treatment of burns. | |
GB0108831D0 (en) | Use of 1,10 and 1,7 and 4,7 phenanthroline, and of 7,8 benzoquinline and of phenanthridine and their derivatives in the treatment of cystic fibrosis and other | |
WO1999024052A3 (en) | Use of protein h as cytostatic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |